This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Non-Inferiority Study Comparing the Subunit Vaccines Influvac and Agrippal in China

This study has been completed.
Information provided by:
Solvay Pharmaceuticals Identifier:
First received: May 11, 2006
Last updated: October 31, 2006
Last verified: October 2006
In the study Influvac will be compared to Agrippal, another subunit influenza vaccine that is already on the market in China. The main objective of the study is to show that both vaccines are comparable with regard to efficacy. In addition, safety and efficacy data with Influvac will be assessed in the Chinese population.

Condition Intervention Phase
Healthy Biological: Influvac; subunit influenza vaccine Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Prevention
Official Title: A Randomized, Endpoint-Blind, Parallel Group Study to Demonstrate the Non-Inferiority of the Subunit Influenza Vaccine Influvac® to the Subunit Influenza Vaccine Agrippal® in Healthy Children, Adults and Elderly in China.

Resource links provided by NLM:

Further study details as provided by Solvay Pharmaceuticals:

Primary Outcome Measures:
  • HI titers 4 weeks after vaccination (efficacy) and safety and tolerability

Secondary Outcome Measures:
  • HI derived parameters: seroprotection, seroconversion and mean fold increase 4 weeks after vaccination

Estimated Enrollment: 900
Study Start Date: March 2006

Ages Eligible for Study:   3 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • signed and dated informed consent
  • being healthy
  • mental health enough to understand the study, the informed consent form and the questionnaire

Exclusion Criteria:

  • known to be allergic to constituents of the vaccine
  • having an autoimmune disorder, taking immunomodulating drugs or having immune disfunction secondary to HIV
  • having had a documented serious adverse reaction to previous influenza vaccination
  • having had documented influenza infection or vaccination in the six months prior to the start of the study
  • having received any other vaccines, immunoglobulins or investigational drugs in the month prior to the start of the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00325260

Site 1
Nanjing, China
Sponsors and Collaborators
Solvay Pharmaceuticals
Study Director: Global Clinical Director Solvay Solvay Pharmaceuticals
  More Information Identifier: NCT00325260     History of Changes
Other Study ID Numbers: S201.3.121
Study First Received: May 11, 2006
Last Updated: October 31, 2006

Keywords provided by Solvay Pharmaceuticals:
healthy subjects

Additional relevant MeSH terms:
Immunologic Factors
Physiological Effects of Drugs processed this record on July 26, 2017